Cass report urges ‘extreme caution’ in prescribing puberty blockers to trans youth
Sign up for more LGBTQ+ news and updates at TrueQueer.
The Cass report, an independent review into the provision of healthcare for trans youth in England, has urged clinicians to use “extreme caution” when prescribing puberty blockers to trans youth. The report, spanning 400 pages and published recently, highlighted weak evidence on the impact of puberty-blocking hormones on gender dysphoria and criticized historical studies for their poor quality.
Puberty-blocking hormones are medications that suppress unwanted puberty-related changes and have been considered physically reversible by NHS England in the past. However, the Cass report raised concerns about the lack of robust evidence supporting the positive or negative effects of these hormones on trans youth.
NHS England commissioned the independent review led by Dr. Hilary Cass in response to the increasing referrals to the country’s only youth gender clinic. The report recommended a decentralized approach to care provision in England through the establishment of regional hubs. It also highlighted the conflicting views on how to provide appropriate care for trans youth and emphasized the need for a more holistic approach to healthcare.
Dr. Cass emphasized the importance of expanding capacity across the country, grounded in pediatric services, and delivered consistently. She called for a robust research environment to gather evidence on long-term outcomes and the efficacy of different interventions to inform future care decisions.
The report recommended separate pathways for pre-pubertal children and their families, as well as a follow-through service for individuals aged 17-25 transitioning to adult gender clinics. While puberty blockers will remain available for clinic trials for patients aged 16 and up, clinicians were advised to exercise extreme caution and provide a clear clinical rationale for prescribing these hormones to under-18s.
Some experts, like Dr. Aiden Kelly, director of Gender Plus, expressed agreement with some of the report’s recommendations but raised concerns about its focus on detransitioners at the expense of the majority. Kelly highlighted the need for a comprehensive service that addresses not only gender needs but also other aspects of young people’s well-being.
However, both Kelly and Stonewall’s director of campaigns and human rights, Robbie de Santos, expressed doubts about the full implementation of the report’s recommendations. They cited issues with the readiness of new regional hubs and questioned whether the suggested changes would be effectively put into practice.
Dr. Hilary Cass, a former consultant in pediatric disability and President of the Royal College of Paediatrics and Child Health, was tasked with leading the independent review. Cass has a history of advocating for child healthcare and has been recognized for her contributions to the field.
Overall, the Cass report has sparked discussions on the provision of healthcare for trans youth in England, emphasizing the need for caution and evidence-based decision-making in prescribing puberty blockers. As stakeholders navigate the implementation of the report’s recommendations, ongoing dialogue and collaboration will be essential to ensure that trans youth receive the quality healthcare they deserve.
Follow us on: Facebook for more LGBTQ+ news and updates at TrueQueer.
puberty blockers
